Clinical trial · Observational
The Immune Assessment of PD-1 Antibody Therapy in Tumor
The Immune Assessment of PD-1 Antibody Therapy in Tumor - A Case-Control Study
NCT06693440CI-TRIAL-00082620recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This retrospective study will leverage previous immune function monitoring results in conjunction with clinical case data at this medical center.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adverse Event | — | UNRESOLVED | — |
| Efficacy, Team | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PD-1 Inhibitors | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Experimental group
- description
- PD-1 inhibitor combined therapy, 200mg, iv, q3w, 1 year for adjuvant therapy or 2 years for advanced therapy
- interventionNames
- Drug: PD-1 Inhibitors
- label
- Control group
- description
- PD-1 inhibitor mono-therapy, 200mg, iv, q3w, 1 year for adjuvant therapy or 2 years for advanced therapy
- interventionNames
- Drug: PD-1 Inhibitors
Primary outcomes (2)
- measure
- Objective response rate
- timeFrame
- 6 months
- description
- The objective response rate at 6 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age ≥18 years. 2. Pathologically confirmed malignant tumors. 3. Complete medical records. 4. Assessable immune function test data. Exclusion Criteria: 1. Age \<18 years. 2. No confirmed tumor pathology. 3. Untraceable medical records. 4. Non-assessable immune function tests.
References
Publications (0)
Data not yet available
No reference posted for this study.